Skip to main content
Figure 5 | Journal of Hematology & Oncology

Figure 5

From: Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells

Figure 5

Alemtuzumab long-term efforts on CD34+ cells secondary culture. CD34+ cells were isolated from day 35 cultures and put into secondary culture with the original cytokine combination (50 ug/ml SCF, TPO and Flt-3 Ligand) and 10% human serum, with or without 10 μg/ml alemtuzumab (control group). After a further 7 to 14 days of culture, cells were harvested to analyze CD34 and CD52 expression profiles. A: Expression profiles of CD34 and CD52 at Day 7 and Day 14 of secondary cultures. B: Absolute expansion fold of CD34+ cells of secondary cultures. The absolute expansion fold is calculated by the absolute CD34+ cells number as compare to secondary culture initiate CD34+ numbers. The results are from three separate experiments.

Back to article page